AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
By Adria Calatayud
AstraZeneca reported increases in revenue and profit for the third quarter, after strong sales of cancer drugs offset the effect of patent expirations to lift the group's top line.
The U.K. drugmaker said Friday that it made a net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
Excluding exceptional items, core earnings per share were $2.79, a 19% increase from a year earlier when excluding currency changes. The result beat analysts' expectations for $2.59, according to consensus estimates provided by Visible Alpha.
Quarterly revenue came to $16.21 billion, up 7% at constant exchange rates. Analysts had forecast the company's quarterly revenue at $15.99 billion, according to consensus estimates provided by Visible Alpha.
AstraZeneca said it benefited from double-digit sales growth in its oncology, respiratory and immunology, and rare disease therapeutic areas, which allowed it to offset hits from generic competition for aging medicines Farxiga and Brilinta.
The company reiterated its 2026 guidance, with Chief Executive Pascal Soriot saying AstraZeneca is on track to deliver its 2030 ambition and to sustain growth through the next decade.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 30, 2026 03:40 ET (07:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
What 7 Key Market Indicators Are Telling Investors Right Now
Don’t Overlook the Income Side of Fixed Income
United States